Abstract
Non-invasive prenatal testing (NIPT) using cell-free fetal DNA (cffDNA) is an area of development in screening for Down's syndrome (DS) that has generated great interest. Analysis of cffDNA found in the maternal blood circulation from 4-weeks gestation is a more accurate screening blood test than is currently available on the NHS. The implementation of NIPT for DS in the NHS has the potential to increase the number of DS cases detected while reducing the number of invasive tests needed and their associated miscarriages. This article will provide an overview of NIPT for DS, the current evidence and what questions need to be answered before implementation within the NHS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
